^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    ARID1A K1238fs + FGFR2 R210Q

    i
    Other names: ARID1A, AT-Rich Interaction Domain 1A, SWI/SNF-Related, Matrix-Associated, Actin-Dependent Regulator Of Chromatin Subfamily F Member 1, AT-Rich Interactive Domain-Containing Protein 1A, AT Rich Interactive Domain 1A (SWI-Like), ARID Domain-Containing Protein 1A, SWI/SNF Complex Protein P270, BRG1-Associated Factor 250a, SWI-Like Protein, Osa Homolog 1, SMARCF1, C1orf4, BAF250, HOSA1, OSA1, AT Rich Interactive Domain 1A (SWI- Like), Chromatin Remodeling Factor P250, BRG1-Associated Factor 250, OSA1 Nuclear Protein, Brain Protein 120, BAF250a, BM029, MRD14, FGFR2, BEK, CD332, CEK3, CFD1, ECT1, JWS, K-SAM, KGFR, TK14, TK25, Fibroblast growth factor receptor 2
    Entrez ID:
    2263; 8289
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    almost3years
    Updated efficacy and ctDNA analysis of patients with TRK fusion lung cancer treated with larotrectinib (ELCC 2022)
    P1, P2 | "ctDNA next-generation sequencing represents a promising technology but its optimal integration into testing NTRK gene fusions or resistance mutations still remains to be determined. Known resistance mutations in NTRK may cause progression, but further studies are warranted."
    Clinical • Circulating tumor DNA
    |
    FGFR2 (Fibroblast growth factor receptor 2) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ARID1A (AT-rich interaction domain 1A) • SMAD4 (SMAD family member 4) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    ARID1A mutation • FGFR2 mutation • FGFR2 fusion • ARID1A K1238fs + FGFR2 R210Q • NTRK1 F589L + NTRK1 G595R • NTRK1 G595R • SMAD4 R361C • NTRK fusion
    |
    Guardant360® CDx • GuardantOMNI
    |
    Vitrakvi (larotrectinib)